Mass Drug Administration with Ivermectin: A promising tool toward malaria elimination
The burden of malaria in The Gambia has substantially declined over the past two decades. However, transmission of the disease persists, especially in the eastern part of the country. The vision of the World Health Organization and the global malaria community is a world free of malaria, with countries accelerating efforts toward elimination by combining interventions tailored to local contexts.
Researchers at the Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine (MRCG at LSHTM) conducted the first cluster-randomised trial to assess the combined effect of mass drug administration (MDA) with ivermectin and dihydroartemisinin-piperaquine on the prevalence of Plasmodium falciparum infection and survival of malaria vectors in settings where the coverage of standard control interventions is high.
Join us as we discuss the results of this trial and what this means for malaria in The Gambia, and elsewhere.
Speakers
- Harouna Dit Massire Soumare, PharmD, Manager Entomology Laboratory/Project Entomologist at MRCG at LSHTM, PhD student
-
Talk: Malaria vector control and transmission dynamic to inform elimination in The Gambia context
- Edgard Dabira, MD, Research Clinician and Clinical Trial Coordinator at MRCG at LSHTM, PhD candidate
-
Talk: Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster randomised controlled trial in The Gambia
Admission
Contact
